UPDATED: Saturday Evening — More from an anonymous source — in comments:
. . . .Various newssources say Takeda wants to take over some R&D people, around 200 to 300.
It would leave 1,800 people to be fired after February 2011. It’s said that Takeda is the only company talking with Merck at the HQ of Merck. So the role of Supervisory Board in the negotiations in The Netherlands is unclear to me.
December 18, 2010 5:44 PM. . . .
I don’t doubt the veracity here, but it is an unconfirmed, off-the-record source (an anonymous comment — left in my box, very early this morning):
Latest news it seems that Takeda is the interested party! Other parties no longer interested. . .
December 18, 2010 5:50 AM. . . .
We’ll keep you posted — could Takeda emerge as the intact buyer, here by mid-February 2011? Takeda is facing a fearsome exclusivity/patent cliff on its oral type II diabetis drug, Actos® (pioglitazone), come early 2011.